  Glioblastoma ( GBM) is the most common and lethal primary malignant glioma in adults. Dendritic cell ( DC) vaccines have demonstrated promising results in GBM clinical trials. However , some patients do not respond well to DC therapy , with survival rates similar to those of conventional therapy. We retrospectively analyzed clinical and laboratory data to evaluate the factors affecting vaccine treatment. Forty-seven patients with Younger age ( < 57 years) , gross total resection , and CCRT and PD-1 For patients receiving DC vaccine adjuvant therapy , better outcomes are predicted in patients with younger age , with TILs or PBMCs with lower PD-1